Westfield Capital Management Company Lp decreased its stake in Jazz Pharmaceuticals Plc (JAZZ) by 8.23% based on its latest 2016Q3 regulatory filing with the SEC. Westfield Capital Management Company Lp sold 146,825 shares as the company’s stock declined 13.87% while stock markets rallied. The institutional investor held 1.64M shares of the major pharmaceuticals company at the end of 2016Q3, valued at $198.98 million, down from 1.78M at the end of the previous reported quarter. Westfield Capital Management Company Lp who had been investing in Jazz Pharmaceuticals Plc for a number of months, seems to be less bullish one the $6.98B market cap company. The stock decreased 0.39% or $0.46 during the last trading session, hitting $116.12. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has declined 25.04% since June 7, 2016 and is downtrending. It has underperformed by 32.46% the S&P500.
Westfield Capital Management Company Lp, which manages about $17.38B and $12.39 billion US Long portfolio, upped its stake in Lions Gate Entmnt Corp (NYSE:LGF) by 588,935 shares to 1.47 million shares, valued at $29.42 million in 2016Q3, according to the filing. It also increased its holding in Visa Inc (NYSE:V) by 251,998 shares in the quarter, for a total of 2.36M shares, and has risen its stake in Servicenow Inc (NYSE:NOW).
Westfield Capital Management Company Lp is a Massachusetts-based institutional investor with more than $17.38 billion AUM in October, 2014. Taken from Westfield Capital Management Company latest Adv, the fund reported to have 61 full and part-time employees. Among which 16 performing investment advisory and research functions. The institutional investor had more than 1200 clients.
Insitutional Activity: The institutional sentiment decreased to 0.81 in 2016 Q3. Its down 0.44, from 1.25 in 2016Q2. The ratio fall, as 61 funds sold all JAZZ shares owned while 113 reduced positions. 41 funds bought stakes while 100 increased positions. They now own 52.49 million shares or 0.51% less from 52.76 million shares in 2016Q2. Bartlett And Llc last reported 0% of its portfolio in the stock. The Japan-based Diam Com Ltd has invested 0.13% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Teachers Retirement Systems Of The State Of Kentucky owns 72,300 shares or 0.11% of their US portfolio. Wfg Advisors Lp last reported 73 shares in the company. Axa holds 0.03% or 62,200 shares in its portfolio. Regions Fin last reported 0.01% of its portfolio in the stock. Epoch Prtnrs last reported 36,686 shares in the company. Blackrock Japan Limited holds 0.03% of its portfolio in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) for 77,214 shares. Wellington Grp Limited Liability Partnership holds 14,150 shares or 0% of its portfolio. Renaissance Group Ltd Llc last reported 0.47% of its portfolio in the stock. The New York-based Jane Street Group Ltd has invested 0% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Creative Planning has 2,180 shares for 0% of their US portfolio. Riggs Asset Managment Inc holds 0% or 75 shares in its portfolio. Hbk Invests Ltd Partnership holds 0.08% of its portfolio in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) for 66,700 shares. Van Eck Corp last reported 32,119 shares in the company.
Insider Transactions: Since July 13, 2016, the stock had 2 insider purchases, and 16 sales for $4.90 million net activity. ENRIGHT PATRICK G sold $86,373 worth of stock or 633 shares. $3.59 million worth of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) was sold by Mulligan Seamus. Another trade for 200 shares valued at $20,618 was made by MILLER MICHAEL PATRICK on Thursday, December 15. Another trade for 608 shares valued at $83,356 was made by Smith Karen L. on Friday, August 12. $227,688 worth of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) was bought by O’Keefe Kenneth W. RIEDEL NORBERT G had sold 633 shares worth $86,373. $93,468 worth of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) shares were sold by McSharry Heather Ann.
Analysts await Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) to report earnings on February, 28. They expect $1.67 earnings per share, down 26.43% or $0.60 from last year’s $2.27 per share. JAZZ’s profit will be $100.38M for 17.38 P/E if the $1.67 EPS becomes a reality. After $2.16 actual earnings per share reported by Jazz Pharmaceuticals plc – Ordinary Shares for the previous quarter, Wall Street now forecasts -22.69% negative EPS growth.
More notable recent Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) news were published by: Benzinga.com which released: “Jazz Pharmaceuticals Remains A Buy At Deutsche Bank Post Q2 Report” on August 11, 2016, also Benzinga.com with their article: “Goldman Sees 26% Upside In Jazz Pharma Shares” published on June 06, 2016, Benzinga.com published: “Jazz Pharma Investors: Did You Catch This Favorable Ruling?” on April 13, 2016. More interesting news about Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) were released by: Benzinga.com and their article: “Martin Shkreli Thinks Jazz Pharmaceuticals Could Be Worth $20 Billion, While …” published on September 12, 2016 as well as Benzinga.com‘s news article titled: “BMO Sees Jazz Pharma As ‘A Rare Breed In Specialty Pharma'” with publication date: June 29, 2016.
According to Zacks Investment Research, “Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company’s goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. They apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.”
Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) Ratings Coverage
Out of 14 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 12 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 86% are positive. $229 is the highest target while $124 is the lowest. The $182.67 average target is 57.31% above today’s ($116.12) stock price. Jazz Pharmaceuticals has been the topic of 22 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The stock of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has “Buy” rating given on Wednesday, February 24 by Stifel Nicolaus. The stock of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has “Buy” rating given on Monday, April 25 by SunTrust. Mizuho downgraded Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) on Tuesday, November 10 to “Neutral” rating. On Wednesday, October 14 the stock rating was initiated by Northland Capital with “Outperform”. Goldman Sachs initiated the stock with “Buy” rating in Monday, June 6 report. The rating was maintained by Mizuho on Wednesday, February 24 with “Neutral”. UBS maintained Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) on Wednesday, May 11 with “Buy” rating. The stock of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has “Buy” rating given on Wednesday, November 9 by Mizuho. The company was maintained on Thursday, August 11 by Deutsche Bank. The stock of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) earned “Outperform” rating by BMO Capital Markets on Wednesday, June 29.
JAZZ Company Profile
Jazz Pharmaceuticals Public Limited Company, incorporated on March 15, 2005, is a biopharmaceutical company. The Firm is focused on developing and commercializing products that address unmet medical needs. The Firm has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company’s lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company’s other product candidates include JZP-110 for treatment of excessive daytime sleepiness (EDS) in narcolepsy and EDS in patients with obstructive sleep apnea (OSA) and JZP-386 for the treatment of EDS in narcolepsy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.